Are Metastatic Breast Cancer Patients Getting the Right Treatment?

According to a recent on line article by Melissa Weber published in www.curetoday.com as many as one in seven women with metastatic breast cancer could be receiving the wrong treatment because of a change in the cancer’s biology when it metastasizes.

“When breast cancer spreads to another part of the body, a HER2-positive cancer could become HER2-negative. Or estrogen receptor-negative cancer could switch to estrogen receptor-positive. Despite different treatment strategies for each, most oncologists rely on what they know about the primary breast tumor to fight the metastasis, says Giuseppe Curigliano, MD, PhD, co-director of the division of medical oncology at the European Institute of Oncology in Milan, Italy. But researchers now believe inhibiting one cancer growth pathway with treatment may activate signaling of a new pathway that allows it to survive and spread.”

A study presented over the summer at the annual ASCO meeting showed that in certain cases when the metastatic lesion was tested, it did not match the primary tumor. There are a few different hypotheses for why this might happen. “Experts suspect that because tumors are made up of different kinds of cancer cells, a small fraction of cells may have a different receptor status. If those cells are more resistant to cancer therapy, the resistant cells may outgrow the rest over time. At the time of recurrence or progression, the overall tumor will have subsequently appeared to have ‘switched.’”

Being aware of the potential that the biologic characteristics of the metastatic lesion might not match that of the primary lesion can have implications for treatment. The researchers quoted in the study suggest that rebiopsy should be performed after considering the safety of the procedure.

To read the full article on line on the curetoday.com website please click here.

For products that can ease side effects of radiation and chemotherapy for breast cancer patients, please click here.

San Antonio Breast Cancer Symposium 2010 Information

The San Antonio Breast Cancer Symposium attracts academic and private physicians and researchers, as well as other health care professionals focused on curing breast cancer, to discuss and learn about new and late-breaking research including experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and pre-malignant breast disease, as well as new findings from clinical trials. With the addition of the AACR as a symposium collaborator, this year’s program will attract more thought-leaders and high-quality proffered papers in basic and translational breast cancer research as well as increase the participation of young investigators by providing superior education and training opportunities for the next generation of breast cancer researchers.
You can view information about the symposium: http://www.sabcs.org/
Abstracts from presentations are available on the website above.
The publication Cure Today has a daily email which reviews highlights of the presentations at the symposium each day. There are also video interviews with some of the presenters. You can view these daily hightlights at: http://media.curetoday.com/sabcs2010/day1.html
Following are two briefs that appear in the Cure Today highlights:
Highlights from the 2009 Symposium: An Update
COMPILED FROM STAFF REPORTS
Physicians, researchers and advocates from all around the world came away from the 2009 SABCS with answers to a number of important questions: Is beginning on an aromatase inhibitor better than switching from tamoxifen? Is Herceptin more effective with or following chemotherapy in HER2-positive breast cancer? Does Avastin slow progression of metastatic breast cancer and by how much? And how well does Xgeva work against bone pain and fracture when compared with Zometa? Get an update on last year's breaking news.
Preventing Cancer in BRCA Mutation Carriers
BY MELISSA WEBER
Every woman with a mutated BRCA1 or BRCA2 gene should have their ovaries removed to lower their risk of ovarian cancer, said speaker Susan Domchek, MD, during an educational session Wednesday at the SABCS. Calling the preventive surgery "mandatory" in BRCA1 and BRCA2 mutation carriers, Domchek said there's no evidence that current ovarian cancer screening is effective.
Click on the abstract name above to be taken to the full article referenced.
To view products that can help with side effects caused by breast cancer treatment, please visit: http://www.LotsToLiveFor.com